← All Envveno Medical CORP filings

Envveno Medical CORP 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
NVNO
Envveno Medical CORP
10-K: enVVeno Medical Shifts Focus to Non-Surgical Venous Valve After VenoValve FDA Rejection
enVVeno Medical Corporation received a non-approvable letter from the FDA for its VenoValve, prompting a strategic pivot to its next-generation enVVe System, a non-surgical venous valve, with pivotal trials expected to begin in 2026.
NASDAQ
NVNO
Envveno Medical CORP
10-K/A: enVVeno Medical Corporation Files Form 10-K/A, Clarifies VenoValve FDA Decision Timeline
enVVeno Medical Corporation amends its Form 10-K to clarify that an FDA decision on its lead product, VenoValve, is expected in the second half of 2025.
NASDAQ
NVNO
Envveno Medical CORP
10-K: enVVeno Medical Corporation Reports 2024 Annual Results, Focus Remains on VenoValve Approval
enVVeno Medical Corporation reports a net loss of $21.8 million for 2024, emphasizing progress towards FDA approval for its VenoValve product.
NASDAQ
NVNO
Envveno Medical CORP
10-K: enVVeno Medical Corporation 2023 Annual Report: VenoValve Trial Completes Enrollment, enVVe Development Accelerated
enVVeno Medical Corporation's 2023 annual report highlights the full enrollment of the SAVVE trial for VenoValve and accelerated development of enVVe, alongside financial results showing increased R&D spending and a net loss.